Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

In a report released today, Glen Santangelo from Barclays maintained a Buy rating on Teva Pharmaceutical, with a price target of $38.00.

End of Quarter Sale - 50% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Santangelo is a 4-star analyst with an average return of 4.7% and a 50.18% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Medline, and McKesson.

In addition to Barclays, Teva Pharmaceutical also received a Buy from TipRanks – PerPlexity’s PerPlexity Drug Manufacturers – Specialty and Generic in a report issued yesterday. However, on the same day, TipRanks – Google reiterated a Hold rating on Teva Pharmaceutical (NYSE: TEVA).

Based on Teva Pharmaceutical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.71 billion and a net profit of $480 million. In comparison, last year the company earned a revenue of $4.23 billion and had a GAAP net loss of $217 million

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TEVA in relation to earlier this year. Earlier this month, Mark Sabag, the EVP, International Markets Commercial of TEVA sold 62,102.00 shares for a total of $1,871,754.28.